Editing Interferon beta-1a (section)

=== COVID-19 ===
{{See also|Coronavirus disease 2019#Research|COVID-19 drug repurposing research}}

Interferon beta-1a administered subcutaneously or intravenously was investigated since March 2020 as a potential treatment in patients hospitalized with [[COVID-19]] in a multinational [[Solidarity trial]] (initially in combination with [[lopinavir]]) but it did not reduce in-hospital mortality compared to local standard of care.<ref name="pmid33264556">{{cite journal | vauthors = Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HB, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PP, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JA, Stevanovikj M, Tacconelli E, Tikkinen KA, Trelle S, Zaid H, Røttingen JA, Swaminathan S | display-authors = 6 | title = Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results | journal = The New England Journal of Medicine | volume = 384 | issue = 6 | pages = 497–511 | date = February 2021 | pmid = 33264556 | pmc = 7727327 | doi = 10.1056/NEJMoa2023184 }}</ref> 

SNG001, an inhalation formulation of interferon beta-1a, is being developed as a treatment for COVID-19 by [[Synairgen]].<ref>{{Cite web|url=https://www.covidtrialathome.com/|title=COVID Trial at Home - developed by Synairgen|website=Covid Trial at Home - developed by Synairgen|access-date=2021-08-08|archive-date=2022-05-07|archive-url=https://web.archive.org/web/20220507151458/https://www.covidtrialathome.com/|url-status=dead}}</ref><ref>{{Cite web|url=https://medicalxpress.com/news/2020-05-university-led-covid19-drug-trial-home.html|title=University-led COVID19 drug trial expands into home testing|website=medicalxpress|access-date=2020-05-27|archive-date=2020-06-06|archive-url=https://web.archive.org/web/20200606011637/https://medicalxpress.com/news/2020-05-university-led-covid19-drug-trial-home.html|url-status=live}}</ref> A pilot trial in hospitalized patients showed higher odds of clinical improvement with SNG001 compared to placebo<ref name="pmid33189161">{{cite journal | vauthors = Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TM | display-authors = 6 | title = Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial | journal = The Lancet. Respiratory Medicine | volume = 9 | issue = 2 | pages = 196–206 | date = February 2021 | pmid = 33189161 | pmc = 7836724 | doi = 10.1016/S2213-2600(20)30511-7 }}</ref> and in January 2021 a phase 3 trial in this population started.<ref>{{cite web | title=Synairgen begins large-scale trial of inhaled COVID-19 treatment | website=PharmaTimes | date=13 January 2021 | url=https://www.pharmatimes.com/news/synairgen_begins_large-scale_trial_of_inhaled_covid-19_treatment_1361172 | access-date=7 August 2021 | archive-date=7 August 2021 | archive-url=https://web.archive.org/web/20210807001259/https://www.pharmatimes.com/news/synairgen_begins_large-scale_trial_of_inhaled_covid-19_treatment_1361172 | url-status=live }}</ref>